+34 679 490 537info@nanbiosis.com

JUMISC

JUMISC

Oocyte holding in the Iberian red deer: Effect of initial oocyte quality and epidermal growth factor addition on in vitro maturation

José Mijares Gordún, and  Francisco M. Sánchez Margallo, Scientific Director and Scientific Coordinator of NANBIOSIS U23. Asisted Reproduction, are co-authors of de article “Oocyte holding in the Iberian red deer (Cervus elaphus hispanicus): Effect of initial oocyte quality and epidermal growth factor addition on in vitro maturation“, published by Reproduction in Domestic Animals.

The scientists have demonstrated that oocyte holding can be used in Iberian red deer oocytes. Interestingly, EGF addition increases the oocytes’ meiotic competence in immediately matured oocytes but not after oocyte holding depending upon initial oocyte quality.

The investigation has been continued in the assisted reproduction laboratory of unit 23 of NANBIOSIS,  equipped with two intracitoplasmatic micromanipulation equipment of the latest generation with IMSI, Laser and Oosight system, embryo biopsy systems, vision systems of the mitotic spindle, with flow cabinets with stereo-microscopes and heated plates, incubators with different gasses systems, equipment and cryopreservation freeze gamete and embryo, among others.

For further information: DOI: 10.1111/rda.13099

Read More

Mesenchymal stem cells or exosomes with fibrin glue mesh fixation modulates the inflammatory reaction in a murine model of incisional hernia

Javier García Casado, Scientific Director of NANBIOSIS U14, Cell Therapy Unit, and Francisco Miguel Sánchez Margallo, Scientific Director of  CCMIJU, are co-author of the publication “Fibrin glue mesh fixation combined with mesenchymal stem cells or exosomes modulates the inflammatory reaction in a murine model of incisional hernia” by Acta Biomaterialia.

In vitro experiments were performed by the ICTS Nanbiosis (Unit 14. Cell therapy at CCMIJU). Exosomes characterization was performed by the ICTS Nanbiosis (Unit 6: Biomaterial processing and Nanostructuring Unit). In vivo experiments were performed by the ICTS Nanbiosis (Unit 22. Animal housing at CCMIJU).

The study has demonstrated a significant increase of anti-inflammatory M2 macrophages and TH2 cytokines when MSCs or exo-MSCs were used. Moreover, the analysis of MMPs, TIMPs and collagen exerted significant differences in the extracellular matrix and in the remodeling process. The in vivo study suggests that the fixation of surgical meshes with FG and MSCs or exo-MSCs will have a beneficial effect for the treatment of incisional hernia in terms of improved outcomes of damaged tissue, and especially, in the modulation of inflammatory responses towards a less aggressive and pro-regenerative profil,

The implantation of surgical meshes is the standard procedure to reinforce tissue defects such as hernias. However, an exacerbated and persistent inflammatory response secondary to this implantation is frequently observed, leading to a strong discomfort and chronic pain in the patients. In many cases, an additional surgical intervention is needed to remove the mesh.

This study shows that mesenchymal stem cells and their exosomes, combined with a fibrin sealant, can be used for the successful fixation of these meshes. This new therapeutic approach, assayed in a murine model of incisional hernia, favors the modulation of the inflammatory response towards a less aggressive and pro-regenerative profile

For further information: DOI: https://doi.org/10.1016/j.actbio.2018.02.014.

 

Read More

Laparoendoscopic Single-Site Surgery Using Handheld Robotic Device

Francisco Miguel Sánchez Margallo, Scientific Director of  CCMIJU and NANBIOSIS U21. Experimental operating rooms, is co-author of the publication “Assessment of Postural Ergonomics and Surgical Performance in Laparoendoscopic Single-Site Surgery Using a Handheld Robotic Device“, by Surgical Innovation (SAGE journal).

The study results show a positive learning curve in ergonomics and surgical performance using the robotic instrument during LESS surgery. This instrument improves the surgeon’s body posture and the needle positioning errors. The use of the robotic instrument is feasible and safe during LESS partial nephrectomy and sigmoidectomy procedures.

The study has been develloped with surgical facilities of high technology that allow in vivo efficacy assays of drugs, nanomedicines, biomaterials and others, performed at unit 21 of NANBIOSIS.

For further information: DOI: 10.1177/1553350618759768

Read More

CCMIJU, partner of NANBIOSIS and the Real Academia Nacional de Medicina and sign a scientific cooperation agreement

The Real Academia Nacional de Medicina and the Centro de Cirugía de Mínima Invasión Jesús Usón, located in Cáceres, have signed a cooperative agreement in the field of training and cooperative R&D projects.

Last 24th April, Professor Joaquín Poch Broto, President of the Real Academia Nacional de Medicina (RANM) and Mr. Luis Casas Luengo, the CCMIJU’s Managing Director, met at Madrid to sign a cooperative agreement.

This event, held at the Yellow Room of the Academia, counted on Prof. Vicente Calatayud (Academic Member), Prof. Luis Pablo Rodríguez (General Secretary), Dr. Francisco Miguel Sánchez Margallo (CCMIJU’s Scientific Director), and its founder, Prof. Usón Gargallo (Honorary President).

On one hand, this agreement focuses on training, mobility, stays, grants… and on the other hand, on didactic activities, carrying out postgrad courses and seminars. It includes the cooperation in R&D projects, specifically in all related to the development of new materials, tools, equipment and new systems in the health field.

The signing considers the cooperation with other companies and research institutes to promote and improve the training of the physicians.

The RANM promotes and carries out activities to develop medicine and spreads its results for the application to society. On 13th March, Academy agreed to support CCMIJU’s candidacy to Princesa de Asturias Awards, in International Category.

The CCMIJU is devoted to research, training and innovation. From 2014 it is one of the 29 existing Singular Scientific Technological Infrastructure (ICTS) in Spain.

Read More

NANBIOSIS ICTS invites groups and companies to discuss Smart Biomaterials and devices for Drug Delivery

On February 22nd, the National School of Health of the Carlos III Health Institute hosted the forum on Smart Biomaterials and biomedical devices for applications in drug delivery and regenerative medicine, organized by the ICTS Nanbiosis, an infrastructure shared by the CIBER-BBN and the Center of Minimally Invasive Surgery Jesus Usón (CCMIJU). This is the first groups/companies meeting organized by Nanbiosis, in which about 70 B2B meetings  were held.

The meeting brought together about 40 participants from 14 research groups (from the CIBER-BBN and the CCMIJU) and 10 companies, which discussed the latest advances in the research lines developed by the groups and platforms of Nanbiosis and on the needs and demands of the industry in smart biomaterials and devices for targeted drug delivery and regenerative medicine.

Jesus Izco, Coordinator of Nanbiosis, presented the new Cutting-Edge Biomedical Solutions“, soon available on the ICTS website. These are integrated solutions to advanced challenges in nanomedicine, biomaterials, medical device, and diagnostic that can be developed by several units under a  one-stop shop model, optimized with the experience and scientific and technical knowledge of the research groups of excellence that manage the involved units. Some of the Cutting-edge biomedical solutions presented in the meeting were preclinical validation of biomaterials, mechanical and surface characterization, biocompatibility and studies of biofilm formation and infections.

The CIBER-BBN prsentations were: “Instructive materials for regenerative medicine” by Miguel Ángel Mateos (NANBIOSIS U5 IP: Elisabeth Engel); “Molecular biomaterials for drug delivery and biomedical applications” byNathaly Veronica Segovia (NANBIOSIS U6 / IP Jaume Veciana and Nora Ventosa); “Advances with micro-nano technologies for in vitro devices and point of care” by Rosa Villa (NANBIOSIS U8 ); “Development of new dosage forms for advanced therapies based on new biomaterials” by José Luis Pedraz (NANBIOSIS U10); “Contact lenses functionalized for the prevention of corneal infections” by Jordi Esquena (NANBIOSIS U12 / IP Carlos Rodríguez); “Combined in-silico and in-vitro models of the cell microenvironment and drug delivery effects in cancer and tissue engineering applications” by Fany Peña (NANBIOSIS U13 / IP Miguel Á. Martínez); “Surface of the biomaterial: the first contact with our body” by  Marisa González (NANBIOSIS U16 ); “Use of biomaterials for the repair of soft tissue defects” by Bárbara Pérez Khöler (NANBIOSIS U17 / IP J M. Bellón and Gemma Pascual); “Controlled release systems based on mesoporous materials with molecular doors for applications in therapy and diagnosis” by Ramón Martínez Máñez (NANBIOSIS U26); “New intelligent devices and biomaterials for the treatment of pathologies of the retina and the nervous system” (Eduardo Fernández); and “Near-infrared responsive scaffolds for biomedical applications” (Nuria Vilaboa).

On the part of the CCMJU, the presentations were the following: “Application of Mesenchymal Stem Cells in preclinical models for surgical and cardiovascular research” by Javier García Casado (NANBIOSIS U14); “Regenerative medicine in animal models of cutaneous healing and diabetic models” by Beatriz Moreno (NANBIOSIS U19); “Preclinical studies of biomaterials” by Idoia Díaz-Güemes (NANBIOSIS U21 /IP: FM Sánchez Margallo); “Porcine model of myocardial infarction as a translational research platform in regenerative medicine” by Verónica Crisóstomo (NANBIOSIS U24).

In the turn of the companies, they presented some collaboration opportunities AJL, i-Vascular, Praxis Pharmaceutical, Technical Proteins Nanobiotechnology and REGEMAT 3D; and they also participated in the Rovi, Viscofan, Biomag and Biogelx Laboratories forum.

These meetings, where links are established between research groups and companies, address issues of business and scientific interest, allowing direct contacts between researchers and business managers.

Read More

The Minimally Invasive Surgery Centre uses HoloLens glasses for medical training and surgical assistance in urology

The Minimally Invasive Surgery Centre, partner of NANBIOSIS,  has developed a software platform to apply mixed reality to medical training and surgical assistance. This will enable the creation of new and more realistic scenarios for medical training and improve surgical results.

The Minimally Invasive Surgery Centre (CCMIJU) uses mixed reality technology, by means of the Microsoft’s HoloLens glasses, to help train future healthcare professionals and provide an assistance tool for complex surgeries.

The institution located in Cáceres has begun using the mixed reality glasses, whose technology combines virtual reality with augmented reality, with the aim of developing, on the one hand, a medical training platform for the anatomy of the pelvic floor, and on the other, a tool for surgical assistance during renal tumor resection procedures.

The use of this technology will benefit both medical students and residents, as well as surgeons. For the former, a software application has been developed and integrated in the HoloLens glasses, that will allow them to visualize and interact with the human anatomy of the pelvis -with and without pathologies- both at muscular, vascular, bone and nervous systems levels. This will facilitate its translation to the real medical practice.

As for the surgeons, this technology will provide access to preoperative studies and real 3D models of the patient in the form of virtual holograms, facilitating the surgical planning and assistance during the abovementioned renal interventions.

The software, developed entirely at the CCMIJU, is in its validation phase in operating rooms. For the first time, and using their own 3D anatomical models, this type of technology is being used for training on the pelvic floor anatomy and for surgical assistance in renal tumor resections.

This R&D line arises from public-private cooperation. The CCMIJU’s team, led by Dr. Francisco Miguel Sánchez Margallo, Scientific Director of this institution, consists of engineers and staff of the Interactive 3D Unit of the Centre who work together with the company CIBEX on the development of new surgical applications. This alliance will enable healthcare professionals to use this emerging technology in challenging surgical interventions and carry out more effective and safe surgeries.

Read More

JUMISC, partner of NANBIOSIS, represents Spain in a European network of 22 countries

The Jesús Usón Minimally Invasive Surgery Centre (JUMISC), partner of NANBIOSIS toguether with CIBER-BBN,  leads a multidisciplinary European research network to improve present urinary stents and prevent their causes of failure.

The idea of creating the network was born from a research, started in 1999 by Doctor Soria, Researcher-Coordinator of the Endoscopic Surgery Area at the JUMISC and the promoter of the mentioned network, representing Spain.

His proposal has been supported by the European and Spanish Urology Association, and funded by the Horizon 2020 Program-Cost Actions (European Cooperation in Science and Technology)

The focus of this Action is to create a multidisciplinary team to identify the problems concerning the urinary stents (design, composition, biomaterial applications, coatings, incrustation, etc.) and to promote future research on this field. In this way, the network will try to reduce adverse effects provoked by the present stents.

This European network (2017-2021), coordinated by Dr. Soria, the Chair of the Action, is composed by 22 European countries and other proposals coming from USA,  Japan, South Korea,  Israel, Canada, Russia, India and it is open to other invited countries to cooperate inside  the organised working groups.

This action will provide, during the next 4 years, an extensive and interdisciplinary R&D program to discover the causes of failure of the present stents and will propose cooperative work in urology and bioengineering field.

This proposal, an initiative of the JUMISC, leaded by Doctor Sánchez Margallo, will contribute to improve healthy-quality of patients, reduce in health care costs, and increase the competitiveness of the European medical device industry.

Read More

II MASTER ON ENDOSCOPY AND MINIMALLY INVASIVE SURGERY IN SMALL ANIMALS (CEyCMI). EXTRAORDINARY DEADLINE FOR ADMISSIONS

A new extraordinary deadline for admissions to the II MASTER ON ENDOSCOPY AND MINIMALLY INVASIVE SURGERY IN SMALL ANIMALS has been set up, from 1st to 14th September. It is organised in collaboration with the Extremadura University ant takes place in Jesús Usón Minimally Invasive Surgery Centre as affiliated entity, offering 60 ECTS-credits.Necessary requirements include having a Veterinary studies degree and a B1 English Certificate. The Master will be held during the academic calendar 2017-2018, according to the established program, that will promote the interaction with the students via an on-line training platform, the direct contact with professors and experts, as well as offering an open material repository.

The Master consists on 4 hands-on training sessions at the JUMISC’s, an external stage in one of our partners centre and the Master’s degree final project.

Further info: www.ccmijesususon.com/ceycmi2017

Read More

JUMISC awarded with the Prize to the Best Research Practice

Last Friday, May 5, JUMISC was awarded in the 1st edition of Extremadura Health Prices, event organised by Sanitaria 2000, text-editor of the Redacción Médica, the most famous and specialised newspaper in its sector.

The contribution of the Extremadura Health Service and the regional health sector were awarded between the 56 nominations included in 14 categories. JUMISC obtained the award of “Best Research Practice”.

The event was held in the convent of San Juan de Dios, in Olivenza-Badajoz, and gathered the JUMISC’s Scientific Director, Mr. Sánchez Margallo (on behalf of the institution),  together with other authorities and health managers.

A prestigious jury decided about winners in accordance to the following classification: The best public hospital, the best hospital service, the best physician, the best primary healthcare, the best health administration, the best research practice, the best private health institution, the best nursery practice, the best social responsibility for health, the best scientific society, the best technological contribution, the best association of patients and the best chemistry practice.

Read More

10th Anniversary of the New Minimally Invasive Surgery Centre (JUMISC)

Next Friday, 21st April, we celebrate the 10th Anniversary of the new JUMISC, betting on training and on research and development activities. 

In its ten years of background we emphasize the following figures:

  • 500 trained physicians,
  • 160 training activities per year
  • More than 100 R&D projects with 7.930.800 € funding
  • 17 patents,
  • The creation of a spin-off,
  • The development of 25 apps,
  • More than 623 scientific collaborators,
  • 500 visits received from more than 500 institutions.

10 years full of training courses and European R&D projects. We are so proud for  the promotion and creation of the  Clúster Sociosanitario of Extremadura (Health Cluster), for obtaining the Good Laboratory Practice to  carry out preclinical trials, for launching a Program of training on Assisted Reproduction, for creating a 3D Department to develop apps, for being included as ICTS in the Spanish Map of Singular Facilities and in the CIBER-CV (Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares).

Jesus Usón Minimally Invasive Surgery Centre (JUMISC), one of NANBIOSIS partners together with CIBER-BBN, is a multidisciplinary institution devoted to research and innovation in health sciences.

Further info about our achievement in:

http://10aniversario.ccmijesususon.com/

Read More